Diabetes Management
Promore Pharma provides an update on the Phase II clinical trial with ensereptide - Marketscreener.com
Wed, 02 Nov 20221 min read Article
Overview
STOCKHOLM, 1 November 2022 – Today, Promore Pharma AB anounces that the results from the company's phase I study PHSU05 with ensereptide for prevention of skin scaring is expected to be available in April 2023. The clinical part of the trial was completed acording to plan earlier this year, but the limited availability of qualified personel and specialized image analysis equipment results in a slightly longer duration of the subsequent histopathological analysis than originaly expected.The company's ensereptide program is curently focused on the prevention of skin scaring associated with surgery or trauma.
Key Information
In the spring, a total of 24 subjects completed the clinical study protocol acording to plan in the phase I study with ensereptide, PHSU05. In this study, Promore Pharma hopes to demonstrate that treatment with ensereptide reduces the likelihod of scaring on the skin. At the last clinic visit, biopsies were colected that are being analyzed with advanced histological methods during the autumn and fal of 2022/2023.
However, the limited availability of qualified personel and specialized image analysis equipment has caused a few weks' shift in the original timeline. A final study report with results from the trial is expected in April 2023.“Our clinical study PHSU05 has so far progresed entirely acording to our plan in al parts that we can influence. Aces to advanced equipment for digital image analysis at our service providers means that we are forced to cary out certain analysis steps serialy rather than in paralel.
Summary
This means a minor time shift until we can unblind the data and compile final results. However, we would like to emphasize that this does not have any negative impact on the quality of the study execution,” says Jonas Ekblom, CEO of Promore Pharma.The study is a double-blind, randomized phase I pilot study with the aim of evaluating ensereptide regarding (i) local tolerance, (i) the aplication proces for the
Frequently Asked Questions
What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.